# Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

> **NCT02474069** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 772 (actual)

## Conditions studied

- Moderate to Severe Plaque-type Psoriasis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT02474069
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-08
- **Primary completion:** 2016-09-15
- **Final completion:** 2016-09-15
- **Target enrollment:** 772 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474069, "Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02474069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*